Related references
Note: Only part of the references are listed.miR-210: a therapeutic target in cancer
Liu Hong et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2013)
MicroRNA-mediated gene regulations in human sarcomas
Subbaya Subramanian et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2012)
High expression of miR-210 predicts poor survival in patients with breast cancer: A meta-analysis
Liu Hong et al.
GENE (2012)
Expression of microRNA 210 associates with poor survival and age of tumor onset of soft-tissue sarcoma patients
T. Greither et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Identification of a Signaling Axis HIF-1α/MicroRNA-210/ISCU Independent of SDH Mutation That Defines a Subgroup of Head and Neck Paragangliomas
Anna Merlo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature
J. PosthumaDeBoer et al.
CLINICAL & EXPERIMENTAL METASTASIS (2011)
Global MicroRNA Expression Profiling Identifies MiR-210 Associated with Tumor Proliferation, Invasion and Poor Clinical Outcome in Breast Cancer
Francoise Rothe et al.
PLOS ONE (2011)
MicroRNAs in Plasma of Pancreatic Ductal Adenocarcinoma Patients as Novel Blood-Based Biomarkers of Disease
Jin Wang et al.
CANCER PREVENTION RESEARCH (2009)
miR-210 promotes osteoblastic differentiation through inhibition of AcvR1b
Yosuke Mizuno et al.
FEBS LETTERS (2009)
An Integrated Approach for Experimental Target Identification of Hypoxia-induced miR-210
Pasquale Fasanaro et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Gene expression programs in response to hypoxia: Cell type specificity and prognostic significance in human cancers
JT Chi et al.
PLOS MEDICINE (2006)
Share Paper
